Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance.

Item

http://www.wikidata.org/entity/Q38650067

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Darunavir/cobicistat for the t ...... genetic barrier to resistance.

@en

type

Item

label

Darunavir/cobicistat for the t ...... genetic barrier to resistance.

@en

prefLabel

Darunavir/cobicistat for the t ...... genetic barrier to resistance.

@en

P1476

Darunavir/cobicistat for the t ...... genetic barrier to resistance.

@en

P2093

Amedeo Capetti

http://www.w3.org/2001/XMLSchema#string

Giuliano Rizzardini

http://www.w3.org/2001/XMLSchema#string

Maria Vittoria Cossu

http://www.w3.org/2001/XMLSchema#string

P2860

Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro

Darunavir: a critical review of its properties, use and drug interactions

Molecular Characterization of Clinical Isolates of Human Immunodeficiency Virus Resistant to the Protease Inhibitor Darunavir

The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health

HIV-1 transmitted drug resistance mutations among antiretroviral therapy-Naïve individuals in Surabaya, Indonesia

Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.

Differential effects of viremia and microbial translocation on immune activation in HIV-infected patients throughout ritonavir-boosted darunavir monotherapy.

Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration

Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance

Pharmacokinetics and safety of boosted elvitegravir in subjects with hepatic impairment.

P304

2689-2702

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2015.1109632

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26612518

http://www.w3.org/2001/XMLSchema#string